General information/AASLD Awards
23 November 2010
Hypovitaminosis D and ethnic differences in insulin resistance
Hong‐Fang Ji – 23 November 2010
Nonalcoholic fatty liver in a developing country is responsible for significant liver disease
Ajay Duseja, Balkrishan Sharma, Amit Kumar, Shweta Kapil, Ashim Das, Radha K. Dhiman, Yogesh K. Chawla – 23 November 2010
Adipose to the rescue: Peripheral fat fuels liver regeneration
Sundararajah Thevananther – 23 November 2010
Liver enzymes and cardiovascular outcomes: A new research agenda
Yusuf Yilmaz, Ramazan Kurt, Cem Kalayci – 23 November 2010
Drug‐induced autoimmune hepatitis caused by anti–tumor necrosis factor α agents
Cumali Efe, Tugrul Purnak, Ersan Ozaslan, Staffan Wahlin – 23 November 2010
Treatment response in patients with autoimmune hepatitis
Christoph Schramm, Christina Weiler‐Normann, Christiane Wiegard, Stefanie Hellweg, Susanne Müller, Ansgar W. Lohse – 23 November 2010
The balancing act of hepatocyte apoptosis
Nicholas A. Shackel – 23 November 2010 – The cell death receptor Fas plays a role in the establishment of fulminant hepatitis, a major cause of drug‐induced liver failure. Fas activation elicits extrinsic apoptotic and hepatoprotective signals; however, the mechanisms by which these signals are integrated during disease are unknown. Tissue inhibitor of metalloproteinases 3 (TIMP3) controls the critical sheddase a disintegrin and metalloproteinase 17 (ADAM17) and may dictate stress signaling.
2010 Hepatology referees (Volumes 51 and 52)
23 November 2010
Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin‐28B genotype
Alexander J. Thompson, Andrew J. Muir, Mark S. Sulkowski, Keyur Patel, Hans L. Tillmann, Paul J. Clark, Susanna Naggie, Jacques Fellay, Dongliang Ge, Jeanette J. McCarthy, David B. Goldstein, John G. McHutchison – 23 November 2010